Detalhe da pesquisa
1.
PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.
Toxicol Pathol
; 44(1): 98-111, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26534939
2.
Researcher or nurse? Difficulties of undertaking semi-structured interviews on sensitive topics.
Nurse Res
; 22(1): 27-31, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25251817
3.
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Int J Cancer
; 129(4): 847-58, 2011 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21328342
4.
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Mol Cancer Ther
; 18(5): 909-919, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30872381
5.
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance.
Nat Commun
; 10(1): 2030, 2019 05 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31048689
6.
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.
Cancer Discov
; 9(2): 230-247, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30373918
7.
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Mol Cancer Ther
; 16(6): 1031-1040, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28292940
8.
Understanding behavior change for women experiencing intimate partner violence: mapping the ups and downs using the stages of change.
Patient Educ Couns
; 62(3): 330-9, 2006 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-16860522
9.
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Cancer Res
; 62(20): 5749-54, 2002 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12384534
10.
End of life care: The experiences of advance care planning amongst family caregivers of people with advanced dementia - A qualitative study.
Dementia (London)
; 15(5): 958-75, 2016 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25187482
11.
Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.
Mol Cancer Ther
; 15(10): 2378-2387, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27439477
12.
Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.
Oncotarget
; 7(52): 86313-86325, 2016 Dec 27.
Artigo
Inglês
| MEDLINE | ID: mdl-27861144
13.
A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.
J Control Release
; 229: 106-119, 2016 05 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27001894
14.
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
ACS Med Chem Lett
; 7(5): 514-9, 2016 May 12.
Artigo
Inglês
| MEDLINE | ID: mdl-27190603
15.
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Sci Transl Med
; 8(325): 325ra17, 2016 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26865565
16.
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
J Med Chem
; 48(2): 392-402, 2005 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-15658853
17.
ZD6126: a novel small molecule vascular targeting agent.
Int J Radiat Oncol Biol Phys
; 54(5): 1497-502, 2002 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-12459377
18.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cancer Discov
; 4(9): 1046-61, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-24893891
19.
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
J Med Chem
; 57(20): 8249-67, 2014 Oct 23.
Artigo
Inglês
| MEDLINE | ID: mdl-25271963
20.
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
J Med Chem
; 56(17): 7025-48, 2013 Sep 12.
Artigo
Inglês
| MEDLINE | ID: mdl-23930994